Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01275222 · ClinicalTrials.gov registry record · Phase 1
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT01275222 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 117 participants.
The verdict
NCT01275222, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
Interventions
- DRUG RAD001
- DRUG Imatinib 600mg/day (Glevec is the brand name for imatinib)
- DRUG Imatinib 800mg/day (Glevec is the brand name for imatinib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2002-11-13 |
| Est. Completion | 2008-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01275222
The ClinicalTrials.gov registry entry for NCT01275222 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which RAD001 is the first listed.
NCT01275222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01275222 about?
NCT01275222 is a clinical study titled "Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors". This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
What is the current status of trial NCT01275222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2002-11-13. Estimated completion is 2008-09-03.
What interventions are being tested in trial NCT01275222?
The interventions under investigation include: RAD001 (DRUG), Imatinib 600mg/day (Glevec is the brand name for imatinib) (DRUG), Imatinib 800mg/day (Glevec is the brand name for imatinib) (DRUG).
Who is sponsoring clinical trial NCT01275222?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.